Search
+
    SEARCHED FOR:

    HETERO

    India, Mexico begin talks for trade pact; aim to boost commerce, investments

    India and Mexico have initiated negotiations for a preferential trade agreement to enhance bilateral trade and investment. The agreement aims to create new economic opportunities while addressing market access, customs procedures, and trade facilitation. Discussions included organising a Mexican business mission to India in early 2027 to improve commercial ties. India had a trade surplus with Mexico, largely due to exports in autos and pharmaceuticals.

    Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption

    Dr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda injection were halted in July for technical evaluation. The new brands are manufactured by Hetero Labs, while distributors say the company may discontinue Obeda injectable supplies. Dr Reddy’s denies a replacement strategy.

    CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbook

    At CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated products to expand their global footprint as geopolitical and supply-chain risks reshape the industry.

    Hetero partners with Richter to develop, market Semaglutide injection globally

    Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic of Ozempic. This collaboration aims to expand global access to diabetes therapies. Regulatory filings are underway, with EU and US submissions planned for 2027. The partnership leverages Hetero's market presence and Richter's European network.

    Hyderabad Police Bust $250 mln cyber-intimidation racket targeting drug maker Hetero Group

    Hyderabad police have uncovered a sophisticated cyber-intimidation scheme. Perpetrators demanded a massive ransom from a Hetero Group employee. They threatened to share false information with the USFDA. This led to serious reputational and regulatory risks for the company. Police have arrested two individuals in connection with the racket.

    Hetero gets WHO prequalification for generic Covid antiviral Paxlovid

    This is the first WHO prequalification for Paxlovid - a combination of nirmatrelvir and ritonavir which is recommended for treating mild and moderate Covid patients at the highest risk of hospital admissions, such as unvaccinated, aged, or immunosuppressed patients.

    The Economic Times
    BACK TO TOP